In a report released yesterday, from Huatai Securities maintained a Buy rating on Simcere Pharmaceutical Group Limited, with a price target of ...
Simcere Pharmaceutical Group Limited has an analyst consensus of Strong Buy, with a price target consensus of HK$19.21.
Based on Simcere Pharmaceutical Group Limited’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$4.15 billion and a net profit of HK$740.4 million. In comparison, last year the company earned a revenue of HK$3.52 billion and had a net profit of HK$276.57 million
In a report released yesterday, from Huatai Securities maintained a Buy rating on CSPC Pharmaceutical Group, with a price target…
In a report released on July 22, from Huatai Securities maintained a Buy rating on Softcare Limited, with a price target of…
In a report released on May 15, from Bank of China maintained a Buy rating on Hua Hong Semiconductor Ltd., with a price target…
Guosheng Securities analyst maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited yesterday and set a price…
In a report released yesterday, from Huatai Securities maintained a Buy rating on MINISO Group Holding Ltd., with a price target…
Citic Securities analyst maintained a Buy rating on Hesai Group Class B on May 28 and set a price target of HK$187.20. The…
